315 related articles for article (PubMed ID: 8631017)
1. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
[TBL] [Abstract][Full Text] [Related]
2. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
[TBL] [Abstract][Full Text] [Related]
4. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
6. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
7. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
[TBL] [Abstract][Full Text] [Related]
8. In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium.
Kraft AS; Adler V; Hall P; Pettit GR; Benjamin WH; Briles DE
Cancer Res; 1992 Apr; 52(8):2143-7. PubMed ID: 1559218
[TBL] [Abstract][Full Text] [Related]
9. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice.
Lukka PB; Paxton JW; Kestell P; Baguley BC
Cancer Chemother Pharmacol; 2010 May; 65(6):1145-52. PubMed ID: 19774378
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128).
Newman RA; Fuentes A; Covey JM; Benvenuto JA
Drug Metab Dispos; 1994; 22(3):428-32. PubMed ID: 8070319
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, tissue distribution, and excretion of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) in dogs.
Cho YB; Kim KH; Kim DK
Drug Metab Dispos; 1995 Nov; 23(11):1280-5. PubMed ID: 8591731
[TBL] [Abstract][Full Text] [Related]
15. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
Foster BJ; Wiegand RA; LoRusso PM; Baker LH
Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
[TBL] [Abstract][Full Text] [Related]
17. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and metabolism of the antiarrhythmic agent [3H]-diprafenone in the rat.
Brunner F; Kolmayr U; Kukovetz WR
Arzneimittelforschung; 1989 Nov; 39(11):1430-5. PubMed ID: 2619776
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats.
Paulson SK; Zhang JY; Breau AP; Hribar JD; Liu NW; Jessen SM; Lawal YM; Cogburn JN; Gresk CJ; Markos CS; Maziasz TJ; Schoenhard GL; Burton EG
Drug Metab Dispos; 2000 May; 28(5):514-21. PubMed ID: 10772629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
